We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precis... Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0148 | -14.8 | 0.1 | 0.1293 | 0.0787 | 22433425 | 0.0950661 | CS |
4 | -0.0297 | -25.8485639687 | 0.1149 | 0.1293 | 0.0787 | 18762479 | 0.09901335 | CS |
12 | -0.3876 | -81.9796954315 | 0.4728 | 0.5916 | 0.0787 | 8169844 | 0.12952392 | CS |
26 | -0.546 | -86.5019011407 | 0.6312 | 1.56 | 0.0787 | 4726961 | 0.23639276 | CS |
52 | -1.7048 | -95.2402234637 | 1.79 | 2.57 | 0.0787 | 2865808 | 0.39826758 | CS |
156 | -3.6148 | -97.6972972973 | 3.7 | 5.85 | 0.0787 | 1122987 | 0.72079342 | CS |
260 | -3.1548 | -97.3703703704 | 3.24 | 7.72 | 0.0787 | 793646 | 1.34218089 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions